HomeGeneticsConditionCLN3 disease
Back to Condition
CLN3 disease
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

CLN3 disease

CLN3 disease is an inherited disorder primarily affecting the nervous system, leading to progressive vision impairment, intellectual disability, movement problems, speech difficulties, and seizures after 4 to 6 years of normal development.

Overview

CLN3 disease is an inherited disorder that primarily affects the nervous system. After 4 to 6 years of normal development, children with this condition develop vision impairment, intellectual disability, movement problems, speech difficulties, and seizures, which worsen over time.

In children with CLN3 disease, problems with vision often begin between the ages of 4 and 8 years. Vision impairment is caused by a breakdown of the light-sensitive tissue at the back of the eye (retinal degeneration), which worsens with age. People with CLN3 disease are often blind by late childhood or adolescence. Also around age 4 to 8, children with CLN3 disease start to fall behind in school. They have difficulty learning new information and lose previously acquired skills (developmental regression), usually beginning with loss of the ability to speak in complete sentences.

Seizures and movement abnormalities often develop in adolescence in people with CLN3 disease. These abnormalities include muscle rigidity or stiffness, clumsiness, slow or diminished movements (hypokinesia), and a stooped posture. Over time, affected individuals lose the ability to walk or sit independently and require wheelchair assistance. Rarely, people with CLN3 disease develop a distorted view of reality (psychosis) or false perceptions (hallucinations). Some affected individuals have an abnormal heart rhythm (arrhythmia) later in life. Most people with CLN3 disease live into early adulthood.

CLN3 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease. All these disorders affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation "CLN," meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype.

Frequency

CLN3 disease is the most common type of NCL, but its exact prevalence is unknown; more than 400 cases have been described in the scientific literature. Collectively, all forms of NCL affect an estimated 1 in 100,000 individuals worldwide.

Causes & Risk Factors

CLN3 disease is caused by mutations in the CLN3 gene, which provides instructions for making a protein that is found in tissues throughout the body. The CLN3 protein is part of many compartments within cells, including lysosomes, which are cellular compartments that digest and recycle different types of molecules. However, the exact function of the CLN3 protein is unclear. Research has shown that this protein is involved in many cellular processes, but it is uncertain which of them is the primary role of the protein, or if these processes instead represent downstream effects.

It is unclear how mutations in the CLN3 gene lead to the characteristic features of CLN3 disease. One CLN3 gene mutation, found in the vast majority of cases, leads to the production of an abnormally short protein. As a result, the abnormal CLN3 protein is broken down or may interfere with normal cellular processes. Other mutations reduce the amount of normal protein or impair its function. It is not known how loss of this protein causes the signs and symptoms of CLN3 disease.

CLN3 disease, like other NCLs, is characterized by the accumulation of proteins and other substances in lysosomes. These accumulations occur in cells throughout the body; however, nerve cells seem to be particularly vulnerable to their effects. The accumulations can cause cell damage leading to cell death. The progressive death of nerve cells in the brain and other tissues leads to the neurological signs and symptoms of CLN3 disease. However, it is unclear how mutations in the CLN3 gene are involved in the buildup of substances in lysosomes.

Learn more about the gene associated with CLN3 disease

  • CLN3

Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names

  • Batten-Mayou disease
  • Batten-Spielmeyer-Vogt disease
  • CLN3-related neuronal ceroid-lipofuscinosis
  • Juvenile Batten disease
  • Juvenile cerebroretinal degeneration
  • Juvenile neuronal ceroid lipofuscinosis
  • Spielmeyer-Vogt disease

Additional Information & Resources

Genetic Testing Information

  • Genetic Testing Registry: Neuronal ceroid lipofuscinosis 3

Genetic and Rare Diseases Information Center

Frequently Asked Questions

Diagnosis usually begins with a comprehensive ophthalmologic exam that reveals specific retinal changes, such as a "bull's eye" maculopathy or pigmentary retinopathy. This is followed by genetic testing for mutations in the CLN3 gene. In some cases, a skin biopsy may be performed to look for characteristic storage material in the cells, although genetic testing is the gold standard for confirmation. Brain MRI may also show specific patterns of white matter changes that support the diagnosis.
Currently, there is no cure for CLN3 disease, and treatment is supportive and palliative. Management focuses on controlling seizures with anticonvulsant medications, providing physical and occupational therapy to maintain mobility and independence for as long as possible, and offering speech therapy to preserve communication skills. Recent research is exploring enzyme replacement therapies and gene therapy, but these are not yet standard clinical treatments.
Before significant retinal degeneration becomes apparent, parents may notice that a child is squinting, sitting closer to the television, or having difficulty with fine motor tasks like writing or buttoning clothes. Subtle changes in behavior, such as increased irritability or withdrawal from social activities, can also occur. Because the disease typically presents after 4 to 6 years of normal development, any sudden regression in school performance or speech fluency in a previously healthy child should prompt an immediate ophthalmological and neurological evaluation.
Most individuals with CLN3 disease live into their early to mid-twenties, though some may survive longer. As the disease progresses, patients typically lose the ability to walk and sit independently, requiring full-time wheelchair assistance and care. Late-stage complications include severe muscle rigidity, difficulty swallowing (dysphagia) which increases the risk of aspiration pneumonia, and in rare cases, cardiac arrhythmias. Psychiatric symptoms such as psychosis or hallucinations may also emerge in later stages.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss